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Background
Invasive fungal infections have emerged as the major causes of morbidity and mortal-
ity associated with cancer chemotherapy, organ transplant, HIV infection, hematopoi-
etic stem cell transplant, and intensive care hospitalization (Walsh et  al. 1992; Groll 
et al. 1996; Minamoto and Rosenberg 1997; Sahbudak et al. 2015; Kanamori et al. 2015; 
Cabezas-Quintario et  al. 2016; Kennedy et  al. 2016). At present, only three structural 
classes of drugs: polyenes, azoles, and echinocandins are available as therapeutic options 
for such infections (Roemer and Krysan 2014). Among these, the polyenes like ampho-
tericin B are the oldest class of antifungal drugs, which are preferred for treating sys-
temic infections, whereas the most widely used class of antifungal drugs are Azoles 
(Maertens and Boogaerts 2000; Della Pepa et al. 2016). The echinocandins are the most 
recent addition to the available range of antifungal agents (Kitamura 2010; Matejuk et al. 
2010; Moudgal and Sobel 2010). These compounds have emerged as an important thera-
peutic option against candidiasis as they exhibit broad fungicidal activity against Can-
dida spp. (Roemer and Krysan 2014).
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However, the major drawbacks seem to be in the usage of standard antifungal ther-
apies, which includes toxicity, low efficacy rates and the development of resistance 
to these drugs, owing to their extensive consumption in recent years (Baixench et al. 
2007; Chakrabarti et  al. 2009; Howard et  al. 2009; Pfaller et  al. 2010). Therefore, to 
combat the problem of rapid increase in life-threatening fungal infections by drug-
resistant fungal strains, there is a constant demand for the development of novel anti-
fungal agents with a different mode of actions. The crucial point in the development 
of new drugs is the identification and characterization of new targets. The available 
antifungal drug targets with various underlying biological mechanisms are: ergosterol 
synthesis, chitin synthesis, glucan synthesis, nucleic acid synthesis, protein synthe-
sis, and microtubules synthesis (Carrillo-Muñoz et  al. 2006). Among them, glucan 
synthesis is one of the most important mechanisms, which leads to the synthesis of 
β-1,3-glucan, a major component of the fungal cell wall. The process is aided by the 
enzyme β-1,3-glucan synthase, which catalyzes the synthesis of β-1,3-glucan poly-
mers (Cabib et al. 1982). The major function of the fungal cell wall is to control the 
internal turgor pressure, and its dynamics are closely related to the growth and divi-
sion of the cell. Hence, any disturbance with its assembly or integrity ultimately leads 
to cell lysis and cell death. Since β-1,3-glucan synthase is unique to fungi and its activ-
ity is essential for cell wall assembly and cell growth, the enzyme has been considered 
as a promising target for the development of less toxic anti-fungal agents (Kurtz and 
Rex 2001). Indeed, echinocandins target the fungal cell wall by competitively inhibit-
ing the synthesis of glucan polymers by binding the glucan synthase complex leading 
to the death of the fungal cell by damaging the cell wall (Cassone et  al. 1981). The 
mode of action of echinocandins perhaps makes this particular class of compounds 
one of the most effective antifungal agents with minimal collateral toxicity in mam-
malian cells (Reboli et al. 2007).
One of the major limitations posed by echinocandins is that they could only be 
administered intravenously (Tattevin et  al. 2014). Although some azoles like vori-
conazole and posaconazole could be administered orally but these antifungal agents 
exhibited higher a risk of drug interactions and increased pharmacokinetic variability 
(Boyd et al. 2004; den Hollander et al. 2006). Therefore, such limitations have led to 
the search for an orally bioavailable small molecule inhibitor that is highly desirable 
for antifungal treatment.
In recent years, pharmacophore based virtual screening is extensively being used to 
develop novel drugs (Shah et al. 2010; Yang 2010). A pharmacophore often serves as 
a template for the desired ligand in search of a potential drug (Van Drie 1997; Güner 
2000; Yang 2010). In the present study, pharmacophore models were developed using 
PHASE (Dixon et al. 2006) [24] to explore new lead compounds. Further, based on the 
alignment of the pharmacophoric points, an atom-based 3D-QSAR model was gener-
ated. The pharmacophore model was employed to screen ZINC database of synthetic 
and natural product molecules (Irwin et al. 2012). The contour maps produced from 
3D-QSAR studies elucidated the essential structural features required for glucan syn-
thase (GS) inhibition that could be used as a guideline for the further design of more 
potent inhibitors.
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Methods
Dataset
A dataset of 42 molecules containing pyridazinone derivatives of Candida albicans 
β-1,3-glucan synthase inhibitors were used for the pharmacophore based 3D-QSAR 
studies. All the molecules with their inhibitory activities were collected from the litera-
ture (Ting et al. 2011; Zhou et al. 2011). The GS inhibitory activities expressed in terms 
of IC50 were then converted to the pIC50 (−log IC50). For selecting the training and test 
set molecules, careful consideration was taken to include diverse molecules as well as 
an optimum proportion of active and less active molecules for the uniform sampling of 
data. Out of the 42 molecules, ~73 % i.e., 31 were used as the training set for the genera-
tion of 3D-QSAR models and the rest ~27 % were used as the test set for external valida-
tion (Table 1). The detail procedure for selecting the training and test sets molecules is 
described in Additional file 1. The pIC50 values for training set spanned over 3 log units. 
Further, to develop the pharmacophore models, the molecules were assigned as actives 
(pIC50 > 6.500) and inactives (pIC50 < 5.640) as given in Table 1.
Ligand preparation
2D structures were drawn using 2D sketcher of Maestro (Maestro 2013), the 3D struc-
ture conversion and minimizations of ligands were performed using LigPrep (Lig-
Prep 2013). Various possible ionization states were generated at pH 7 ±  2.0. In order 
to develop a pharmacophore model, 3D realistic representations of the experimental 
molecular structures are necessary. Since most ligands were flexible, it is important to 
consider a range of thermally accessible conformational states to increase the chances 
of finding geometry close to the putative binding mode. PHASE provides two built-in 
approaches, both of which employ the MacroModel conformational search engine. Con-
formers were generated using ConfGen (Watts et al. 2010) followed by minimization of 
each generated structure using Merck Molecular Force Field (MMFF).
Common pharmacophore hypothesis (CPH) generation
The chemical features or the pharmacophore sites for the molecules were defined using 
built-in six pharmacophoric features (Dixon et  al. 2006) hydrogen-bond acceptor (A), 
hydrogen-bond donor (D), hydrophobic group (H), negatively charged group (N), posi-
tively charged group (P), and aromatic ring (R). The common pharmacophore hypothesis 
was identified by using the active analog approach, in which common pharmacophores 
were collected from the conformations of the set of active ligands using a tree-based 
partitioning technique that groups together similar pharmacophores according to their 
inter-site distances. The tree depth was given as 5 with an initial box size of 32 Å and 
a final box size of 1 Å. Subsequently, the pharmacophores were scored and ranked to 
identify the best candidate hypothesis. The scoring algorithm included the contributions 
from the alignment of site points, vectors, volume overlap, selectivity, number of ligands 
matched, relative conformational energy and activity.
3D‑QSAR model generation and validation
The pharmacophoric points of the best CPH was used for the alignment of the mole-
cules, included in the 3D-QSAR studies. A rectangular grid is defined to encompass the 
Page 4 of 21Meetei et al. SpringerPlus  (2016) 5:965 
Table 1 Training and test set molecules with their observed and predicted activities
Compound R pIC50 observed pIC50 Predicted Fitness score
c Set
1 6.39 6.38 2.74 Test
2 6.20 6.30 2.9 Test
3 6.37 6.31 2.92 Training
4 6.38 6.33 2.56 Training
5a 7.13 7.07 2.72 Training
6a 6.79 9.94 2.71 Test
7a 6.66 6.61 3 Training
8 6.09 6.37 2.79 Training
9a 6.54 6.61 2.81 Training
10a 7.10 7.06 2.85 Training
11b 4.64 4.53 2.06 Training
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Table 1 continued
Compound R pIC50 observed pIC50 predicted Fitness score Set
12a 6.70 6.74 2.95 Training
13 –CH3 5.66 5.95 2.23 Test
14 5.89 5.97 2.78 Training
15 5.77 5.99 2.85 Training
Compound R pIC50 observed pIC50 predicted Fitness score Set
16b 5.33 5.18 2.08 Test
17 5.65 5.64 2.33 Training
18a 6.74 6.43 2.95 Training
19 5.64 5.62 0.81 Training
20 5.82 5.50 2.26 Test
21a 6.92 7.04 2.76 Training
22 5.96 6.04 2.31 Training
23b 5.52 5.46 2.21 Training
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Table 1 continued
Compound R pIC50 observed pIC50 predicted Fitness score Set
24 6.27 5.87 2.34 Test
25 6.04 6.00 2.22 Test
Compound R pIC50 observed pIC50 predicted Fitness score Set
26 H 6.04 6.09 2.11 Training
27b 5.38 5.38 2.7 Training





28 H 6.38 6.21 2.79 Training
29 H 5.96 6.16 2.78 Training
30 F 6.21 6.20 2.78 Test
31 F 6.22 6.14 2.78 Training
Compound R pIC50  
observed
pIC50 predicted Fitness score Set
32 5.66 5.71 2.52 Training
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Compound R pIC50  
observed
pIC50 predicted Fitness score Set
33b 5.55 5.56 2.81 Training
Compound R pIC50 observed pIC50 predicted Fitness score Set
34b 5.05 5.09 2.33 Training
35b 5.21 5.31 2.84 Training
36 6.00 6.16 2.87 Test
37 6.28 6.33 2.87 Training
38 6.21 6.14 2.86 Training
39a 6.6 6.32 2.86 Test
40 6.58 6.32 2.86 Training
Table 1 continued
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space occupied by the aligned ligands. This grid divides the occupied space into N uni-
formly sized cubes, typically 1 Å on each side. Subsequently, the biological activity val-
ues (pIC50) were correlated to the best hypothesis to generate a 3D-QSAR model, which 
mapped necessary structural features of molecules that govern activity. The model was 
generated with 1 Å grid spacing and a maximum number of PLS factors of 4 by choosing 
the atom based 3D-QSAR option. The best 3D-QSAR model was selected on the basis of 
the statistical robustness and validated by predicting the activity of the external test set 
molecules. External validation is a crucial aspect of pharmacophore design as it is con-
sidered as a definitive proof for judging predictability of a model, particularly when the 
model is built for the purpose of predicting activities of compounds in an external test 
set (Boyd et al. 2004). The external predictability of the selected model was determined 
by using the standard deviation of error prediction R2pred (Roy and Roy 2008) for the test 
set calculated according to the following equation:
where, Ypred (Test) and YTest indicate predicted and observed activity values of test set 
compounds respectively, and Y¯Training represent mean activity value of the training set 
molecules.
Virtual screening
To investigate novel scaffolds with potential GS inhibitory activity, in silico screening of 
synthetic compounds (‘lead like’ compound consisting of 2,46,580 molecules) as well as 








Compound R pIC50 observed pIC50 predicted Fitness score Set
41 6.04 5.86 2.87 Training
42 5.72 5.83 2.87 Training
Table 1 continued
a Active pharm set
b Inactive pharm set
c Fitness score measures the alignment of the pharmacophore site points of matching compounds to those of the 
hypothesis. The reference ligand for the hypothesis having an exact match has a perfect fitness score of 3.0
 Indicates the position for R substitution
Page 9 of 21Meetei et al. SpringerPlus  (2016) 5:965 
pharmacophore model. The resulting hits were filtered using Lipinski’s criteria (Lipinski 
et al. 1997) and then the compounds which have fitness score of more than 2 and 1.5 
for synthetic and natural products, respectively, were subjected to ADME studies. The 
relaxed criterion for fitness score for the natural product was used to obtain a significant 
number of hits.
ADME (absorption, distribution, metabolism, and excretion) studies
ADME properties were calculated using QikProp (2013). It calculates regression mode-
ling-based 44 properties of physiochemical and pharmacokinetical relevance using the 
experimental results of over 710 compounds including about 500 drugs. Further, it also 
evaluates the acceptability of hits based on the Lipinski’s rule of five, provides ranges for 
comparing a particular molecule’s properties with those of 95 % of known drugs, and 
retrieve most similar drugs available.
Results and discussion
Pharmacophore modeling and 3D‑QSAR studies
The pharmacophore models were constructed by selecting a minimum of four and a 
maximum of five pharmacophoric sites. Consequently, from a list of 9 variant combi-
nations a total of 5887 five-featured CPHs belonging to eight types, AAHRR, AHHRR, 
AAAAR, AAARR, AAAHH AAAAH, AAAHR, and AAHHR were subjected to rigorous 
scoring analysis with respect to actives using default parameters for site, vector, and vol-
ume. Reference relative conformational energy (kJ/mol) was incorporated in the score, 
and ligand activity, expressed as pIC50, was included with a default weight. Hypotheses 
generated from this process were subsequently scored with respect to the seven inac-
tives, using a weight of 1.0. The best hypothesis AAARR.594 was selected for further 
study on the basis of the highest survival score (Table 2) as well as according to the best 
scoring statistical parameters generated from pharmacophore based 3D-QSAR models 
(Table  3). The AAARR.594 hypothesis consists of three hydrogen bond acceptors (A) 
and two aromatic rings (R) (Fig. 1). The distances and angles between different sites of 
AAARR.594 are given in Table 4.
The generated pharmacophore should be able to differentiate between active and 
inactive molecules, to avoid unwanted molecules during virtual screening. To validate 
the pharmacophore model, it was mapped to inactive and active compounds (Fig. 2). A 
wrong hypothesis would show better mapping result with inactive molecules. However, 
from Fig. 2 it is evident that the pharmacophore model mapped well in case of active 
than the inactive molecules, thus justifying the pharmacophore model for using in 
screening.
Further, for constructing the atom-based 3D-QSAR model of AAARR.594 hypoth-
esis, the training set compounds were aligned on the pharmacophoric features (Fig. 3) 
and was explored by PLS analysis with one to four PLS factors. The predictive power of 
each model was evaluated by the test set compounds. A summary of the statistical data 
for 3D-QSAR analysis of AAARR.594 hypothesis is listed in Table 5. Different statisti-
cal parameters such as R2, Q2, SD, and RMSE were taken into consideration to exam-
ine the robustness of the 3D-QSAR models and the model with four PLS factors was 
found to be the best. The large value of F (F = 135.30) indicates a statistically significant 
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regression model, which is also supported by the small value of statistical significance 
(P  =  5.277−17), an indication of a high degree of confidence. Furthermore, the small 
value of standard deviation (SD = 0.1368) of the regression and root-mean-square error 
(RMSE = 0.1788) and the higher value of the QSAR model stability (stability = 0.4923) 
indicates that the data used for model generation is the best for the QSAR analysis. The 
Fig. 1 Pharmacophore hypothesis AAARR.594 characterized by three hydrogen bond acceptors and two 
aromatic rings. a Distances (in Å) and b angles (°) between different pharmacophoric features
Table 4 Distance and angles between different sites of AAARR.594
Site1 Site2 Distance (Å) Site1 Site2 Site3 Angle
A2 A4 7.887 A4 A2 A5 10.8
A2 A5 10.025 A4 A2 R10 29.3
A2 R10 11.868 A4 A2 R11 20.4
A2 R11 7.893 A5 A2 R10 18.8
A4 A5 2.713 A5 A2 R11 10
A4 R10 6.304 R10 A2 R11 8.9
A4 R11 2.79 A2 A4 A5 136.3
A5 R10 4.017 A2 A4 R10 113
A5 R11 2.635 A2 A4 R11 79.9
R10 R11 4.249 A5 A4 R10 25.1
A5 A4 R11 57.2
R10 A4 R11 33.1
A2 A5 A4 32.9
A2 A5 R10 107.5
A2 A5 R11 31.3
A4 A5 R10 138.2
A4 A5 R11 62.9
R10 A5 R11 76.3
A2 R10 A4 37.7
A2 R10 A5 53.7
A2 R10 R11 16.7
A4 R10 A5 16.7
A4 R10 R11 21
A5 R10 R11 37
A2 R11 A4 79.7
A2 R11 A5 138.7
A2 R11 R10 154.4
A4 R11 A5 59.9
A4 R11 R10 125.9
A5 R11 R10 66.7
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model with PLS factor four has the highest Q2 (Q2 = 0.827) together with high Pearson-
R value (Pearson-R =  0.9103) and R2 (R2 =  0.954), suggesting a close correspondence 
between predicted and actual IC50 activity values.
Since the difference between R2 and Q2 is <0.3 (0.954–0.827 = 0.127) the model is con-
sidered to be good and reliable (Eriksson et al. 2003; Eriksson 2008). Moreover, the high 
R2pred value (0.711) shows that the model has strong predictive power and significance.
The plots for experimental against predicted activities of the training and test set 
ligands are given in Fig.  4. All the values for the training and test set molecules were 
plotted around the best fit line demonstrating the significance of the predicted model. 
Furthermore, the best fitted model was employed to predict the biological activities of 
training and test set molecules as shown in Table 1.
To check the superiority of the generated 3D-QSAR model based on the highest 
scoring pharmacophore hypothesis over the rest of the pharmacophore hypotheses, a 
3D-QSAR model was developed from the least scoring pharmacophore hypothesis 
AAAHH.338. The statistical result of the generated 3D-QSAR model is given in Addi-
tional file 2: Table S1. The low statistical parameters such as R2 = 0.8684, Q2 = 0.5952, 
Fig. 2 Pharmacophore AAARR.594 mapped on inactive ligands (a) and active ligands (b)
Fig. 3 Alignment of the training set molecules on the best scoring pharmacophore AAARR.594
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Table 5 Summary of  PHASE 3D-QSAR statistical results of  AAARR.594 hypothesis, best 
model is shown in italic font
a Number of factor used in the analyses
b (SD) the standard deviation of regression
c (R2) coefficient of determination
d (F) the ratio of the model variance to the observed activity variance
e (P) significance level of F when treated as a ratio of Chi squared distributions
f (Stability) stability of the model predictions to changes in the training set composition
g (RMSE) the RMS error in the test set predictions
h (Q2) directly analogous to R2 but based on the test set predictions
i (Pearson‑R) value for the correlation between the predicted and observed activity for the test set
j (R2pred) Predictive R
2, Standard deviation of error prediction
No. of  
factorsa
SDb R‑squaredc Fd Pe Stabilityf RMSEg Q‑squaredh Pearson‑Ri R2
pred
j
1 0.3265 0.7089 70.60 2.909e−009 0.7744 0.2226 0.7318 0.8101 0.656
2 0.2281 0.8628 88.10 8.336e−013 0.7296 0.2170 0.7450 0.8900 0.698
3 0.1613 0.9339 127.20 4.879e−016 0.5590 0.2015 0.7801 0.9011 0.689
4 0.1368 0. 9542 135.30 5.277e−017 0.4923 0.1953 0.8268 0.9103 0.711
Fig. 4 Fitness graph between observed activity v/s PHASE predicted activity of a training and b test set 
molecules
Fig. 5 3D-QSAR contour map in the context of a Hydrogen bond donor represented on molecule 42; b 
hydrophobic interactions shown on molecule 5 and c 1; d Electron withdrawing contours overlapped on 
molecule 10 and e 3; blue cubes indicate favorable while red cubes unfavorable coefficients; circles signifies the 
substitution position under consideration for the contour map analysis
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Table 6 Lead molecules obtained from pharmacophore screening
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and R2pred = 0.412 suggest that the 3D-QSAR model derived from AAARR.594 hypoth-
esis could be the best for further studies.
3D‑QSAR contour map analysis
The atom-based 3D-QSAR results can be visualized as a cluster of cubes representing 
the pharmacophore regions, the blue cubes indicating favorable and the red ones unfa-
vorable for activity. Specific structural features or functional groups, having blue and red 
cubes may increase or decrease activity, respectively. A pictorial representation of the 
contour maps representing hydrogen bond acceptor, hydrophobic and electron with-
drawing properties for the best QSAR model is shown in Fig. 5.
Hydrogen bond donor contour map analysis
The hydrogen bond donor contour map applied to the molecule 42 is shown in Fig. 5a. 
A cluster of red cubes can be seen on the NH2 group of the phenylamine substitution at 
the R10 pharmacophoric position. The red contour signifies unfavored region for activ-
ity and, therefore, the substitution with hydrogen bond donor group at this position 
reduced the GS inhibitory activity.
Hydrophobic contour map analysis
As shown in Fig. 5b, a large blue contour map is observed near the sulfonamide tail of 
compound 5 which has naphthalene group substitution at the A2 position of the phar-
macophoric feature and hence has higher activity. However in the case of molecule 1, 
Table 7 Calculated ADME properties of top 14 hits using QikProp
a Predicted molecular weight in g/mol (mol_MW) (acceptable range: 150–650)
b Predicted Octanol/water partition coefficient (QlogP o/w) (acceptable range −2 to 6.5)
c Predicted aqueous solubility in mol/L (QPlogS) (acceptable range −6 to 0.5)
d Predicted Caco‑2 cell permeability in nm/s (<25 is poor and >500 is high)
e Predicted brain/blood partition coefficient in ml blood/g brain (QPlogBB) (Acceptable range −3.0 to 1.2)
f Predicted apparent MDCK cell permeability in nm/s (QPPMDCK) (<25 poor)
g Percentage of human oral absorption (<25 % is poor and >80 % is high)









1 ZINC40390784 491.508 4.344 −7.103 283.006 −1.661 126.417 96.262
2 ZINC57742232 349.425 1.579 −4.142 174.722 −1.624 111.303 76.327
3 ZINC09823898 473.505 4.047 −7.408 122.68 −2.058 73.068 88.025
4 ZINC09087176 420.485 4.658 −6.158 1697.891 −0.627 1250.849 100
5 ZINC21010902 405.449 2.26 −3.882 637.579 −0.766 549.709 90.375
6 ZINC18222209 406.476 2.96 −5.739 313.892 −1.142 345.347 88.966
7 ZINC81275318 314.404 3.999 −5.111 1361.266 −0.539 1067.441 100
8 ZINC03522823 342.375 1.668 −3.596 47.592 −1.645 57.928 66.738
9 ZINC12140774 487.443 3.321 −4.663 615.698 −0.608 764.772 96.313
10 ZINC69708581 333.355 2.197 −4.176 495.559 −0.878 231.624 88.048
11 ZINC72283844 341.366 1.384 −3.292 345.62 −1.083 234.06 80.484
12 ZINC38269114 434.488 5.388 −6.92 644.585 −1.148 307.755 95.814
13 ZINC13375730 352.343 2.666 −4.664 342.987 −1.094 155.611 87.933
14 ZINC13375727 352.343 1.54 −3.829 194.191 −1.313 84.141 76.916
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(Fig. 5c) the particular position has more red cubes and is substituted with a tert-butyl 
moiety, which is less hydrophobic, thus resulting in lower activity. Again at the A4 posi-
tion of the pharmacophoric site, the pyridazinone ring has long acyclic chain substi-
tutions with various linkers. Molecule 21 with linker oxygen is more active since the 
substituted moiety is enclosed in the favored blue contours, whereas molecule 23 pro-
jects its sulfonamide linker into the red contours (shown in Additional file 3: Figure S1a) 
and, therefore, has lower activity. Further, large blue contours can be seen at the R10 
position of the pharmacophoric feature for compound 39, the m-chlorofluorobenzene 
substitution is responsible for the higher activity, which overlapped with the blue con-
tours. Conversely, in the case of molecule 34 the cyclohexyl moiety is less hydrophobic 
and it extends into the red contours, resulting in lower activity (Additional file 3: Figure 
S1b).
Electron withdrawing contour map analysis
The favored region of electron withdrawing blue contoured map, covering the molecule 
10 shown in Fig. 5d can be explained on the basis of the benzoxazolemethyl substitu-
tion on the sulfonamide tail at the A2 pharmacophoric position. The nitrogen and oxy-
gen atoms present in the oxazole ring make the moiety more electronegative, which is 
favorable at this position and hence has higher activity. In contrast, the methoxyethane 
group of molecule 3 at A2 pharmacophoric position (Fig. 5d) is less electronegative and 
thus has lower activity as compared to molecule 10. Additionally, the red contour map 
at the R10 pharmacophoric position makes the molecules with electronegative substitu-
tions less active. For example, molecule 42 with aniline substitution at that position has 
low activity, which falls into the red contour map (Additional file 3: Figure S1c). Simi-
larly, molecule 35 having pyridine substitution also has low activity.
Virtual screening
The selected hypothesis AAARR.594 was used to screen 2,46,580 synthetic and 41,490 
natural product compounds available in ZINC database. For searching the database, 
the minimum criteria used was matching of all the five pharmacophore features, with 
default tolerance on matching the features to each of the five inter-feature distances. 
Each molecule of the database was represented by a maximum of 100 conformations and 
conformers were generated using ConfGen. A total of 672 compounds, consisting of 560 
synthetic and 112 natural product hits, were screened, after filtering using Lipinski crite-
ria. Additionally, to narrow down the number of potential hits, the matches were filtered 
Fig. 6 Lead molecules with a total of a 11 synthetic compounds and b 3 natural product hits retrieved from 
pharmacophore virtual screening shown on the five pharmacophoric features of AAARR.594 hypothesis
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using fitness score. Only those hits were selected, which had fitness score of more than 
2 and 1.5 for synthetic and natural product compounds, respectively. A total of 11 syn-
thetic compounds survived the process, and 3 hits were retrieved from the natural prod-
uct database (Table 6). These lead molecules overlapped with the five pharmacophoric 
features as shown in Fig. 6.
ADME prediction
An analysis of 44 physicochemically important descriptors and pharmaceutically rel-
evant properties of the 14 lead compounds were carried out using Qikprop. Only the 
significant descriptors including Lipinski’s, which are reported to be essential for pre-
dicting drug-like properties of molecules were considered (Table 7). They were: molecu-
lar weight in g/mol (acceptable range of 150–650), Octanol/water partition coefficient 
(QlogP o/w, −2 to 6.5), aqueous solubility (QPlogS in mol/L, −6 to 0.5), Caco-2 cell 
permeability (QPPCaco in nm/s, <25 poor and >500 high), Brain/blood partition coef-
ficient (QPlogBB in ml blood/g brain, −3.0 to 1.2), apparent MDCK cell permeability 
(QPPMDCK in nm/s, <25 poor, higher the value of MDCK cell, higher is the cell perme-
ability), Percent human oral absorption (>80 % is high, <25 % are poor). The partition 
coefficient (QPlogPo/w) and water solubility (QPlogS), which are critical for estimation 
of absorption and distribution of drugs within the body, ranged between 0.8 and 5.3 and 
−8.092 to −3.102, respectively. Cell permeability (QPPCaco), a key factor governing 
drug metabolism and its access to biological membranes ranged from 62.460 to 812.195. 
The predicted apparent MDCK cell permeability, QPPMDCK ranges from 24.691 to 
2955.977  nm/s. Blood–brain partition coefficient (QlogBB) ranges from −3.0 to 1.2. 
The percentage human oral absorption of the compounds ranged from 66.7 to 100 %. 
The pharmacokinetic properties of the lead molecules are within the acceptable range, 
defined for human use hence indicating their potential as drug-like molecules.
Natural product hits
The lead molecules from the natural product database that survived the screening pro-
cess are found to be present in the medicinal plants Erythrina variegate and Psoralea 
corylifolia (Meetei et al. 2014). The ZINC entry ZINC382691140 is an isoflavonoid, pre-
sent in the stem bark of Erythrina variegate (Xiaoli et al. 2006). Entries ZINC13375727 
and ZINC13375730 are found in the seed of Psoralea corylifolia (Gupta et  al. 1990). 
These plants are used in the folklore system of medicine in various parts of the world. 
Erythrina variegate is used in various treatments such as fever, joint pains, skin diseases 
and also to relieve from earache and toothache. Additionally, the extract from the plant 
has shown significant antimicrobial activity (Rahman et al. 2007; Sahoo et al. 2012). Sim-
ilarly, the medicinal plant Psoralea corylifolia is used in many diseases including vari-
ous skin diseases, nephritis, cardiovascular diseases, cancer, and osteoporosis. The plant 
extract was shown to have antifungal, antibacterial, antitumor, antioxidant and anti-
inflammatory activities (Chopra et al. 2013; Zhang et al. 2016).
The discovery of natural products from the pharmacophore screening process could 
be an alternative source for the detection of novel medicinal plant remedies with better 
safety and efficacy profiles.
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Validation by prediction of known inhibitors
Four known inhibitors of β-1,3-glucan synthase: enfumafungin, ergokonin A, arun-
difungin and ascosteroside were collected from literature (Onishi et  al. 2000). The 2D 
to 3D conversion, and optimization of the molecules were done as described above 
(“Ligand preparation” section). The molecules were aligned on the generated pharma-
cophore (AAARR.594) and their biological activities were predicted using the 3D-QSAR 
model. The observed and predicted biological activities of the compounds are compa-
rable (Additional file 2: Table S2) suggesting that this model has accurate predictability.
Conclusion
The present report portrays different pharmacophore hypotheses of pyridazinone deriv-
atives as inhibitors against glucan synthase. 3D-QSAR models were generated based 
on the alignment of these pharmacophores. A five point pharmacophore with three 
hydrogen bond acceptors (A), two aromatic rings (R) as pharmacophore features was 
used to build the 3D-QSAR model with good statistical significance and predictive abil-
ity. Hypothesis AAARR.594 was observed more accurate than other models, with good 
R2 = 0.954, Q2 = 0.827. Additionally, visualization of the contour maps provided detail 
information of the relationship between structure and activity, and hence offer clues for 
designing more potent analogs. Further, the pharmacophore model was employed to 
screen against the database of natural product and synthetic compounds. The 672 hits 
retrieved during the study were evaluated using multiple criteria yielding 14 leads. Fur-
ther investigation of lead molecules using ADME prediction suggested that their phar-
macokinetic properties were found to be in an acceptable range.
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